Comparison of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrent endometriosis

Comparison of the effectiveness of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrence after laparoscopic surgery in patients with endometriosis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170917036227N5

Enrollment

130

Registered

2020-12-16

Start date

2020-12-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention 1: Intervention group 1: Dienogest tablets will be taken daily for 3 months and then cyclically for the next 3 months (every month from day 10 of the cycle for 2 weeks). Intervention 2: I

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Women aged 18-45 years old Endometriosis confirmation via laparoscopy and histopathologic assessmnet

Exclusion criteria

Exclusion criteria: Pregnancy or Breast Feeding Plan to become pregnant Amenorrhea (no more menstruation - equal to 3 months in the last 6 months) Undiagnosed genital bleeding Recent use of hormonal agents Contraindications to the use of progesterone Having a risk factor for decreased bone density Use of acitretin, anticoagulants such as warfarin, antidiabetic drugs, aperitif and, artemether, atazanavir, barbiturates, bexarotene, Boceprevir, bosentan, thrombogenic drugs, clobazam, anticonvulsant drugs (carphenazine, Topiramate, valproic acid, lamotrigine, phenytoin ...), Darunavir, Deferasirox, Efavirenz, Felbamate, Griseofulvin, Mifepristone, Nelfinavir, Neuruppin, Selegiline, Thalidomide, Tranexamic Acid and Voriconazole

Design outcomes

Primary

Measure	Time frame
Recurrence of endometriosis. Timepoint: Six months after the start of the intervention. Method of measurement: Transvaginal ultrasound.;Pelvic pain. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Dysmenorrhea. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Dyspareunia. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Side effects. Timepoint: Three and six months after the start of the intervention. Method of measurement: check list.	—

Measure

Time frame

Recurrence of endometriosis. Timepoint: Six months after the start of the intervention. Method of measurement: Transvaginal ultrasound.;Pelvic pain. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Dysmenorrhea. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Dyspareunia. Timepoint: Three and six months after the start of the intervention. Method of measurement: Visual Analog Scale (VAS).;Side effects. Timepoint: Three and six months after the start of the intervention. Method of measurement: check list.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Haniyeh Roodi

Tehran University of Medical Sciences

behroozmoogooie@yahoo.com+98 21 7771 9922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026